Advertisement
UK markets open in 3 hours
  • NIKKEI 225

    37,928.78
    +300.30 (+0.80%)
     
  • HANG SENG

    17,585.31
    +300.77 (+1.74%)
     
  • CRUDE OIL

    83.83
    +0.26 (+0.31%)
     
  • GOLD FUTURES

    2,345.10
    +2.60 (+0.11%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • Bitcoin GBP

    51,477.28
    +55.19 (+0.11%)
     
  • CMC Crypto 200

    1,390.30
    +7.73 (+0.56%)
     
  • NASDAQ Composite

    15,611.76
    -100.99 (-0.64%)
     
  • UK FTSE All Share

    4,387.94
    +13.88 (+0.32%)
     

Analysts’ Ratings for FibroGen and Its Peers in April 2018

Analysts’ Ratings for FibroGen and Its Peers in April 2018

FibroGen (FGEN) is a biopharmaceutical company involved in the discovery and development of first-in-class therapeutics. The drug is in Phase 3 of development for the treatment of anemia in chronic kidney disease. The company has adopted a global approach to the development and commercialization of its product candidates.